JP2019216735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019216735A5 JP2019216735A5 JP2019149000A JP2019149000A JP2019216735A5 JP 2019216735 A5 JP2019216735 A5 JP 2019216735A5 JP 2019149000 A JP2019149000 A JP 2019149000A JP 2019149000 A JP2019149000 A JP 2019149000A JP 2019216735 A5 JP2019216735 A5 JP 2019216735A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- nucleic acid
- chimeric molecule
- bont
- serotype
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims 44
- 108030001720 Bontoxilysin Proteins 0.000 claims 23
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 23
- 230000035772 mutation Effects 0.000 claims 19
- 102000039446 nucleic acids Human genes 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 18
- 238000006467 substitution reaction Methods 0.000 claims 18
- 230000004048 modification Effects 0.000 claims 12
- 238000012986 modification Methods 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 108091005804 Peptidases Proteins 0.000 claims 8
- 239000004365 Protease Substances 0.000 claims 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 241000193155 Clostridium botulinum Species 0.000 claims 4
- 230000004075 alteration Effects 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- 206010013952 Dysphonia Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 230000005945 translocation Effects 0.000 claims 3
- 208000008238 Muscle Spasticity Diseases 0.000 claims 2
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims 2
- 206010044074 Torticollis Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 206010039722 scoliosis Diseases 0.000 claims 2
- 201000002849 spasmodic dystonia Diseases 0.000 claims 2
- 230000001148 spastic effect Effects 0.000 claims 2
- 208000018198 spasticity Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010002153 Anal fissure Diseases 0.000 claims 1
- 208000016583 Anus disease Diseases 0.000 claims 1
- 208000012219 Autonomic Nervous System disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000000289 Esophageal Achalasia Diseases 0.000 claims 1
- 208000029728 Eyelid disease Diseases 0.000 claims 1
- 208000009531 Fissure in Ano Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- 208000015592 Involuntary movements Diseases 0.000 claims 1
- 206010023644 Lacrimation increased Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000026025 Muscle tone disease Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 108091005461 Nucleic proteins Proteins 0.000 claims 1
- 206010030136 Oesophageal achalasia Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000036496 Pelvic floor dyssynergia Diseases 0.000 claims 1
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 1
- 208000008630 Sialorrhea Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000004350 Strabismus Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 201000000621 achalasia Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000002898 anismus Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010005159 blepharospasm Diseases 0.000 claims 1
- 230000000744 blepharospasm Effects 0.000 claims 1
- 206010006514 bruxism Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 201000002866 cervical dystonia Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000037315 hyperhidrosis Effects 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 230000004317 lacrimation Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 claims 1
- 230000003957 neurotransmitter release Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002851 oromandibular dystonia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653214P | 2012-05-30 | 2012-05-30 | |
| US61/653,214 | 2012-05-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017095111A Division JP6574218B2 (ja) | 2012-05-30 | 2017-05-12 | 操作されたボツリヌス神経毒素 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019216735A JP2019216735A (ja) | 2019-12-26 |
| JP2019216735A5 true JP2019216735A5 (enExample) | 2020-02-20 |
| JP6839239B2 JP6839239B2 (ja) | 2021-03-03 |
Family
ID=48050254
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514989A Active JP6336970B2 (ja) | 2012-05-30 | 2013-03-13 | 操作されたボツリヌス神経毒素 |
| JP2017095111A Active JP6574218B2 (ja) | 2012-05-30 | 2017-05-12 | 操作されたボツリヌス神経毒素 |
| JP2019149000A Active JP6839239B2 (ja) | 2012-05-30 | 2019-08-15 | 操作されたボツリヌス神経毒素 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514989A Active JP6336970B2 (ja) | 2012-05-30 | 2013-03-13 | 操作されたボツリヌス神経毒素 |
| JP2017095111A Active JP6574218B2 (ja) | 2012-05-30 | 2017-05-12 | 操作されたボツリヌス神経毒素 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9598685B2 (enExample) |
| EP (2) | EP2854840B1 (enExample) |
| JP (3) | JP6336970B2 (enExample) |
| KR (1) | KR102060355B1 (enExample) |
| CN (2) | CN108178801B (enExample) |
| AU (2) | AU2013267957B2 (enExample) |
| BR (1) | BR112014029585A2 (enExample) |
| CA (3) | CA2874587C (enExample) |
| DK (2) | DK3372239T3 (enExample) |
| EA (1) | EA029275B1 (enExample) |
| ES (2) | ES2847241T3 (enExample) |
| HU (2) | HUE037310T2 (enExample) |
| IL (1) | IL235934B (enExample) |
| MX (2) | MX359480B (enExample) |
| NZ (1) | NZ702310A (enExample) |
| PL (2) | PL2854840T3 (enExample) |
| PT (2) | PT3372239T (enExample) |
| SG (2) | SG11201407784UA (enExample) |
| TR (1) | TR201802754T4 (enExample) |
| UA (1) | UA116985C2 (enExample) |
| WO (1) | WO2013180799A1 (enExample) |
| ZA (1) | ZA201408757B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| MX359480B (es) | 2012-05-30 | 2018-09-28 | President And Fellows Of Harvard College Star | Neurotoxina botulínica diseñada. |
| JP6156954B2 (ja) * | 2012-11-21 | 2017-07-05 | イプセン バイオイノベーション リミテッド | タンパク分解性にプロセシングされたポリペプチドの製造方法 |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US9913875B2 (en) * | 2015-03-16 | 2018-03-13 | California Institute Of Technology | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making |
| RU2746736C2 (ru) * | 2015-03-26 | 2021-04-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Сконструированный ботулинический нейротоксин |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| UA127310C2 (uk) | 2016-05-16 | 2023-07-19 | Презідент Енд Феллоуз Оф Гарвард Колледж | Спосіб очищення і активації ботулінічного нейротоксину |
| SG11201810210UA (en) * | 2016-06-08 | 2018-12-28 | Childrens Medical Center | Engineered botulinum neurotoxins |
| PT3475432T (pt) * | 2016-06-23 | 2022-08-02 | Hopitaux Paris Assist Publique | Vetores virais para tratamento de hiperatividade neurogénica do detrusor |
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| EP3504226A1 (en) * | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11400136B2 (en) | 2017-06-19 | 2022-08-02 | President And Fellows Of Harvard College | Methods and compositions for treating a microbial infection |
| CN112105379A (zh) * | 2017-09-29 | 2020-12-18 | 儿童医学中心公司 | 神经毒素样毒素及其用途 |
| WO2019126502A1 (en) | 2017-12-20 | 2019-06-27 | Allergan, Inc. | Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation |
| TWI810228B (zh) * | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
| KR20200115584A (ko) * | 2018-01-30 | 2020-10-07 | 칠드런'즈 메디컬 센터 코포레이션 | 바실루스 시스템을 이용한 보툴리눔 신경독소의 생산 |
| US11707510B2 (en) * | 2018-02-16 | 2023-07-25 | Preclinics Discovery Gmbh | Nucleic acid-based botulinum neurotoxin for therapeutic use |
| SE542539C2 (en) * | 2018-02-26 | 2020-06-02 | Toxotech Ab | Chimeric botulinum neurotoxin heavy chain binding domain |
| US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
| GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| TW202426039A (zh) | 2020-03-16 | 2024-07-01 | 英商艾普森生物製藥有限公司 | 肢體痙攣之治療 |
| GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
| US20240016904A1 (en) * | 2020-11-25 | 2024-01-18 | Vetmed Therapeutics, Inc. | Methods of treating superficial digital flexor tendon injuries, deep and superficial muscle/tendon contracture, navicular syndrome, and suspensory ligament inflammation and injuries in quadruped animals |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| JP2024513191A (ja) | 2021-03-30 | 2024-03-22 | イプセン バイオファーム リミテッド | 疼痛及び炎症性障害の処置 |
| CN117396217A (zh) | 2021-03-30 | 2024-01-12 | 益普生生物制药有限公司 | 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗 |
| WO2022225267A1 (ko) | 2021-04-19 | 2022-10-27 | 엠브릭스 주식회사 | 보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물 |
| MA66538B1 (fr) | 2021-09-16 | 2026-03-31 | Ipsen Biopharm Limited | Bont/a modifiée destinée à être utilisée dans le traitement de la dystonie cervicale |
| CA3228712A1 (en) | 2021-09-23 | 2023-03-30 | Nicolae GRIGORE | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
| GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
| AU2022392458A1 (en) | 2021-11-22 | 2024-05-02 | Ipsen Biopharm Limited | Treatment of pain |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| CN114410683B (zh) * | 2022-01-12 | 2023-11-28 | 中国人民解放军空军军医大学 | 一种基于Cre-lox重组系统的RIM3-RNAi及其应用 |
| CN114369623B (zh) * | 2022-01-12 | 2023-07-07 | 中国人民解放军空军军医大学 | 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用 |
| GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| CN119823215A (zh) * | 2023-10-13 | 2025-04-15 | 北京博特维克生物技术有限公司 | 高效快速重组表达神经毒素蛋白的多肽及其方法 |
| AU2023471835A1 (en) | 2023-11-01 | 2026-04-30 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
| WO2025093845A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
| CN118388606B (zh) * | 2024-04-25 | 2025-09-23 | 武汉大学 | 一种结合蛋白Bntifitin及其在制备用于治疗冠状病毒感染的药物中的应用 |
| KR102790255B1 (ko) * | 2025-01-23 | 2025-04-07 | 엠브릭스 주식회사 | 재조합 보툴리눔 독소 및 이를 함유하는 약학 조성물 |
| CN120775067B (zh) * | 2025-07-07 | 2026-03-03 | 西北农林科技大学 | 一种毒性增强型神经毒素重组蛋白及应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| ATE215832T1 (de) | 1994-05-09 | 2002-04-15 | William J Binder | Botulinumtoxin zur reduktion von migraine - kopfschmerzen |
| DE69511860T2 (de) | 1994-05-31 | 2000-02-10 | Allergan, Inc. | Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine |
| GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| EP1105153A4 (en) * | 1996-08-28 | 2005-01-19 | Ophidian Pharm Inc | POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM) |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| US7148041B2 (en) | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
| AU2005216547B2 (en) | 2004-02-24 | 2009-03-12 | Allergan, Inc. | Botulinum toxin screening assays |
| KR100668570B1 (ko) | 2004-06-28 | 2007-01-16 | 입센 리미티드 | 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물 |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| EP1861419B1 (en) | 2005-03-15 | 2011-06-29 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| US7985554B2 (en) | 2005-10-14 | 2011-07-26 | Wisconsin Alumni Research Foundation | Botulinum neurotoxin A receptor and the use thereof |
| DE102005051789B4 (de) | 2005-10-28 | 2014-08-07 | Toxogen Gmbh | Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen |
| FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
| FR2907680B1 (fr) | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
| FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
| US8586081B2 (en) | 2007-09-20 | 2013-11-19 | University Of Massachusetts | Detoxified recombinant botulinum neurotoxin |
| US8445650B2 (en) | 2007-09-25 | 2013-05-21 | Thomas Jefferson University | Mutant botulinum neurotoxin serotype A polypeptide and uses thereof |
| FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
| ES2592314T3 (es) | 2008-08-29 | 2016-11-29 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxinas clostridiales con persistencia modificada |
| CN101386648B (zh) * | 2008-09-25 | 2012-05-30 | 中国人民解放军军事医学科学院微生物流行病研究所 | 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途 |
| TW201023928A (en) | 2008-11-12 | 2010-07-01 | Kythera Biopharmaceuticals Inc | Systems and methods for delivery of biologically active agents |
| WO2010120766A1 (en) * | 2009-04-14 | 2010-10-21 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| US8440204B2 (en) | 2009-04-30 | 2013-05-14 | Wisconsin Alumni Research Foundation | Subtype of Closteridium botulinum neurotoxin type A and uses thereof |
| MX359480B (es) | 2012-05-30 | 2018-09-28 | President And Fellows Of Harvard College Star | Neurotoxina botulínica diseñada. |
| RU2746736C2 (ru) | 2015-03-26 | 2021-04-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Сконструированный ботулинический нейротоксин |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| SG11201810210UA (en) | 2016-06-08 | 2018-12-28 | Childrens Medical Center | Engineered botulinum neurotoxins |
| EP3504226A1 (en) | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
-
2013
- 2013-03-13 MX MX2014014540A patent/MX359480B/es active IP Right Grant
- 2013-03-13 US US14/403,768 patent/US9598685B2/en active Active
- 2013-03-13 DK DK18151492.8T patent/DK3372239T3/da active
- 2013-03-13 JP JP2015514989A patent/JP6336970B2/ja active Active
- 2013-03-13 HU HUE13714747A patent/HUE037310T2/hu unknown
- 2013-03-13 SG SG11201407784UA patent/SG11201407784UA/en unknown
- 2013-03-13 SG SG10201606666XA patent/SG10201606666XA/en unknown
- 2013-03-13 AU AU2013267957A patent/AU2013267957B2/en active Active
- 2013-03-13 DK DK13714747.6T patent/DK2854840T3/en active
- 2013-03-13 KR KR1020147036798A patent/KR102060355B1/ko active Active
- 2013-03-13 PL PL13714747T patent/PL2854840T3/pl unknown
- 2013-03-13 BR BR112014029585A patent/BR112014029585A2/pt not_active Application Discontinuation
- 2013-03-13 TR TR2018/02754T patent/TR201802754T4/tr unknown
- 2013-03-13 EP EP13714747.6A patent/EP2854840B1/en active Active
- 2013-03-13 CA CA2874587A patent/CA2874587C/en active Active
- 2013-03-13 ES ES18151492T patent/ES2847241T3/es active Active
- 2013-03-13 CN CN201810059379.1A patent/CN108178801B/zh active Active
- 2013-03-13 ES ES13714747.6T patent/ES2661033T3/es active Active
- 2013-03-13 HU HUE18151492A patent/HUE053147T2/hu unknown
- 2013-03-13 NZ NZ702310A patent/NZ702310A/en unknown
- 2013-03-13 CN CN201380040738.4A patent/CN104736166B/zh active Active
- 2013-03-13 PT PT181514928T patent/PT3372239T/pt unknown
- 2013-03-13 PT PT137147476T patent/PT2854840T/pt unknown
- 2013-03-13 CA CA3248592A patent/CA3248592A1/en active Pending
- 2013-03-13 WO PCT/US2013/030737 patent/WO2013180799A1/en not_active Ceased
- 2013-03-13 EP EP18151492.8A patent/EP3372239B1/en active Active
- 2013-03-13 CA CA3170993A patent/CA3170993A1/en active Pending
- 2013-03-13 UA UAA201414110A patent/UA116985C2/uk unknown
- 2013-03-13 EA EA201492203A patent/EA029275B1/ru unknown
- 2013-03-13 PL PL18151492T patent/PL3372239T3/pl unknown
-
2014
- 2014-11-26 MX MX2018011854A patent/MX2018011854A/es unknown
- 2014-11-27 IL IL235934A patent/IL235934B/en active IP Right Grant
- 2014-11-28 ZA ZA2014/08757A patent/ZA201408757B/en unknown
-
2017
- 2017-02-13 US US15/431,694 patent/US10190110B2/en active Active
- 2017-05-12 JP JP2017095111A patent/JP6574218B2/ja active Active
-
2018
- 2018-01-18 AU AU2018200409A patent/AU2018200409B2/en active Active
-
2019
- 2019-01-18 US US16/252,083 patent/US10844362B2/en active Active
- 2019-08-15 JP JP2019149000A patent/JP6839239B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519362A5 (enExample) | ||
| JP2019523015A5 (enExample) | ||
| RU2017134357A (ru) | Сконструированный ботулинический нейротоксин | |
| FI3481852T3 (fi) | Uusi botulinum-neurotoksiini ja sen johdannaisia | |
| US12478663B2 (en) | Use of botulinum neurotoxin in the treatment of sialorrhea | |
| JP2019533430A5 (enExample) | ||
| JP2022046597A5 (enExample) | ||
| JP2019528042A5 (enExample) | ||
| US7888469B2 (en) | Post-translation modification and clostridial neurotoxins | |
| JP2021514674A5 (enExample) | ||
| CN116333158A (zh) | 嵌合神经毒素 | |
| JP2004536778A (ja) | 変化した生物学的持続性を有する改変クロストリジウム神経毒 | |
| TW202033539A (zh) | 陽離子型神經毒素 | |
| JP2019214575A (ja) | 無毒性神経毒誘導体を用いる治療方法 | |
| US20240327472A1 (en) | Modified clostridial neurotoxins | |
| CN101460190A (zh) | 肉毒毒素的神经毒组分的高频率应用 | |
| JP2015504304A (ja) | ポリ−グリシンを伴う修飾神経毒及びその使用 | |
| WO2009015840A2 (en) | Polypeptide for targeting of neural cells | |
| EP2435091A2 (en) | Methods of treating chronic neurogenic inflammation using a modified clostridial toxin | |
| CN109415750A (zh) | 活化的梭菌神经毒素的生产 | |
| RU2019108257A (ru) | Сконструированный ботулинический нейротоксин | |
| RU2020131317A (ru) | Биогибрид ботулинического нейротоксина | |
| NZ747619B2 (en) | Chimeric neurotoxins | |
| NZ749400A (en) | Production of activated clostridial neurotoxins |